Parsortix PR1
It enables translational researchers to capture and harvest circulating tumor and other target cells from blood samples ranging from 100 μL to 40 mL, offering enhanced flexibility for downstream analyses.
Parsortix PR1
Capture and harvest circulating tumour cells from blood
Simple. Easy. Flexible. Customisable.
The Parsortix® PR1 system gives translational researchers the power to capture and harvest circulating tumour and other cells of interest from as little as 100 μL blood samples, providing greater flexibility in downstream analysis.
The Parsortix PR1 system is designed to address the need for:
Highly enriched cell populations
Epitope independence, agnostic to cell phenotype
Research flexibility
Viable cells
CTC clusters
Simple, easy process
Patented step separation technology
Microfluidic technology captures cells, based on size and deformability, as whole blood flows through “steps” within the disposable, plastic Parsortix cassette
Health conditions investigated
The Parsortix PR1 system captures cancer cells from blood, as well as foetal cells from maternal blood. Peer reviewed publications evidence the efficacy of the system with a wide range of cancer types including:
- Breast
- Ovarian
- Research flexibility
- Lung
- Prostate
- Simple, easy process
Flexible downstream molecular analysis
Choose from in-vitro staining or harvesting cells for:
- FISH
- qPCR
- IHC
- WGA
- NGS
- Enumeration
Parsortix technology is a unique method for capturing and harvesting intact circulating tumour cells (CTCs) and CTC clusters from whole blood for downstream analysis
CTCs are cancer cells that have detached from the primary tumour and entered the circulation. They are extremely rare in the blood and are often referred to as “a needle in a haystack”.
- As well as being functional cancer cells, CTCs play a critical role in initiating metastasis and are therefore a focus of cancer research and personalised medicine
- By harvesting viable CTCs, Parsortix technology enables comprehensive profiling of cancer cells in a non-invasive, repeatable manner
Parsortix® technology uses a patented microfluidic technology in the form of a single use cassette to capture and then harvest CTCs from whole blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood cells
